Retrospective analysis of the curative effect of Kanglaite injection on pancreatic cancer
Abstract
Objective To systematically evaluate the curative effect of Kanglaite Injection (KLT) in the treatment of pancreatic cancer (PC) by retrospective analysis. Methods The clinical data of 172 patients with pancreatic cancer were analyzed, and the therapeutic effect, survival time and tumor markers of patients receiving Kanglaite injection combined with conventional chemotherapy were compared with those receiving conventional chemotherapy. Results The univariate results showed that the two groups had WBC, LY#, MO#, NE#, ALB, FFA, CA199, CA125 in age, sex, tumor site, stage of pancreatic cancer, radiotherapy and metastasis, and laboratory indexes. Multivariate analysis showed that the use of KLT in pancreatic cancer patients was significantly related to gender and survival outcome, and KLT could prolong the survival of PC patients. In addition, Chi-square test showed that patients with KLT could reduce the influence on monocyte count and albumin abnormality, which suggested that patients with KLT could reduce the adverse reactions. Conclusion Kanglaite injection combined with conventional radiotherapy and chemotherapy plays a significant role in improving therapeutic effect, improving immune function and prolonging survival expression, and will not increase the incidence of serious adverse reactions. It is a safe and effective comprehensive treatment scheme.
Copyright (c) 2025 Xian Miao, Shu Dong, Ling Zhang, Xiaolin Wen, Jikai Ruan, Dawei Qiao, Hongjuan Ji, Pei Cao, Shuijie Shen
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.